Dr. Andrew V. Grainger, MD

Dr. Grainger practices at Columbus Oncology and Hematology Associates - HOPD in Columbus, Ohio.

Dr. Grainger's NPI, 1912903386, was assigned on June 22, 2005. Dr. Grainger graduated from Creighton University School of Medicine - Omaha in 1997. Dr. Grainger holds Ohio license 35.076121.

Dr. Grainger's primary practice is Columbus Oncology and Hematology Associates - HOPD, at 810 Jasonway Ave, Columbus, OH 43214.

Dr. Grainger's primary practice is Columbus Oncology and Hematology Associates - HOPD in Columbus, Ohio. Dr. Grainger is also affiliated with OhioHealth Riverside Methodist Hospital. The medical group on file is OhioHealth Physician Group. Dmand AI also links Dr. Grainger to 4 more hospitals, 3 group practices and clinics and 2 medical groups, each named with a free account. Dr. Grainger's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Grainger practices, 9 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Grainger's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Grainger is board certified in hematology by the American Board of Internal Medicine. Dr. Grainger is licensed in Ohio.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer and lymphoma among the conditions Dr. Grainger treats.

CMS data shows 46,031 Medicare services from Dr. Grainger across 24 procedure codes in 2024, for 504 Medicare patients. Medicare paid $149,937 for them.

CMS counts 504 Medicare patients who saw Dr. Grainger in 2024. The largest group is 65 to 74, with 221 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 3% are also on Medicaid. Their average risk score is 1.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Grainger's median patient age at 72, with 58% women.

In 2024, Dr. Grainger wrote 1,484 Medicare Part D claims for 204 patients. 72% of them were for generic drugs. CMS names the drug for 1,275 of them, across 27 drugs with 11 or more claims each, at $4,186,800 in total drug cost. In 2023, CMS named 1,060 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Grainger for performance year 2024, reported as part of a group. Dr. Grainger accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Grainger as offering telehealth.

Dmand AI links 5 papers to Dr. Grainger, published from 2014 to 2023. The most frequent topics are Genetic Testing. Dr. Grainger's most frequent co-authors are Banu K. Arun, MD, Generosa Grana, MD and Michael T. Walsh, MD.

CMS Open Payments shows 10 general payments to Dr. Grainger from 9 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 64% of the total. Amgen Inc. paid the most, $112.

Dmand AI lists 2 awards for Dr. Grainger, most recently CMS Stage 1 2012 in 2012.

Dr. Grainger graduated from Creighton University School of Medicine - Omaha in 1997. Dr. Grainger is a member of ASCO.

Dr. Grainger is in network with 18 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.